Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus.

Ogg M, Jonsson CB, Camp JV, Hooper JW.

Viruses. 2013 Nov 8;5(11):2704-20. doi: 10.3390/v5112704.

2.

In vitro and in vivo activity of ribavirin against Andes virus infection.

Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H.

PLoS One. 2011;6(8):e23560. doi: 10.1371/journal.pone.0023560. Epub 2011 Aug 10.

3.

DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS).

Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW.

PLoS One. 2012;7(4):e35996. doi: 10.1371/journal.pone.0035996. Epub 2012 Apr 27.

4.

Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine.

Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW.

J Virol. 2003 Sep;77(18):9894-905.

5.

A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen LA, Hooper JW.

J Virol. 2014 Jan;88(2):811-9. doi: 10.1128/JVI.02906-13. Epub 2013 Nov 6.

6.

Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.

Hooper JW, Ferro AM, Wahl-Jensen V.

J Virol. 2008 Feb;82(3):1332-8. Epub 2007 Nov 21.

7.

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, Hammerbeck CD, Schiltz J, Royals M, Ballantyne J, Hooper JW, Bradley DS.

PLoS Negl Trop Dis. 2015 Jun 5;9(6):e0003803. doi: 10.1371/journal.pntd.0003803. eCollection 2015.

8.

A lethal disease model for hantavirus pulmonary syndrome.

Hooper JW, Larsen T, Custer DM, Schmaljohn CS.

Virology. 2001 Oct 10;289(1):6-14.

9.

Depletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian Hamsters.

Hammerbeck CD, Brocato RL, Bell TM, Schellhase CW, Mraz SR, Queen LA, Hooper JW.

J Virol. 2016 Jun 24;90(14):6200-15. doi: 10.1128/JVI.00304-16. Print 2016 Jul 15.

10.

Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.

Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB.

Antimicrob Agents Chemother. 2013 Oct;57(10):4673-80. doi: 10.1128/AAC.00886-13. Epub 2013 Jul 15.

11.

T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome.

Hammerbeck CD, Hooper JW.

J Virol. 2011 Oct;85(19):9929-44. doi: 10.1128/JVI.05356-11. Epub 2011 Jul 20. Erratum in: J Virol. 2012 Apr;86(7):4043.

12.

Hantavirus pulmonary syndrome.

Macneil A, Nichol ST, Spiropoulou CF.

Virus Res. 2011 Dec;162(1-2):138-47. doi: 10.1016/j.virusres.2011.09.017. Epub 2011 Sep 17. Review.

PMID:
21945215
13.

Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters.

McElroy AK, Smith JM, Hooper JW, Schmaljohn CS.

Virology. 2004 Aug 15;326(1):130-9.

14.

The Syrian hamster model of hantavirus pulmonary syndrome.

Safronetz D, Ebihara H, Feldmann H, Hooper JW.

Antiviral Res. 2012 Sep;95(3):282-92. doi: 10.1016/j.antiviral.2012.06.002. Epub 2012 Jun 15. Review.

15.

Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H.

J Virol. 2011 Dec;85(23):12781-91. doi: 10.1128/JVI.00794-11. Epub 2011 Sep 14.

16.

DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome.

Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao JA, Matsushita H, Sullivan EJ.

Sci Transl Med. 2014 Nov 26;6(264):264ra162. doi: 10.1126/scitranslmed.3010082.

17.

Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus.

Safronetz D, Zivcec M, Lacasse R, Feldmann F, Rosenke R, Long D, Haddock E, Brining D, Gardner D, Feldmann H, Ebihara H.

PLoS Pathog. 2011 Dec;7(12):e1002426. doi: 10.1371/journal.ppat.1002426. Epub 2011 Dec 15.

18.

A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Hooper JW, Josleyn M, Ballantyne J, Brocato R.

Vaccine. 2013 Sep 13;31(40):4314-21. doi: 10.1016/j.vaccine.2013.07.025. Epub 2013 Jul 24.

19.

Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters.

Wahl-Jensen V, Chapman J, Asher L, Fisher R, Zimmerman M, Larsen T, Hooper JW.

J Virol. 2007 Jul;81(14):7449-62. Epub 2007 May 2.

20.

Andes virus recognition of human and Syrian hamster beta3 integrins is determined by an L33P substitution in the PSI domain.

Matthys VS, Gorbunova EE, Gavrilovskaya IN, Mackow ER.

J Virol. 2010 Jan;84(1):352-60. doi: 10.1128/JVI.01013-09.

Supplemental Content

Support Center